Study Summary
This trial is testing a new cancer treatment that uses a patient's own immune cells to fight their cancer.
- Cervical Cancer
Treatment Effectiveness
Study Objectives
3 Primary · 11 Secondary · Reporting Duration: Up to 60 months
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
5 Treatment Groups
Cohort 1 LN-145 monotherapy
1 of 5
Cohort 2 LN-145 monotherapy
1 of 5
Cohort 5 Retreatment Cohort
1 of 5
Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only
1 of 5
Cohort 4 - Non-enrolling Cohort
1 of 5
Experimental Treatment
189 Total Participants · 5 Treatment Groups
Primary Treatment: LN-145 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What medical conditions does LN-145 typically address?
"LN-145 is an effective treatment option for malignant neoplasms, microsatellite instability high, and unresectable melanoma." - Anonymous Online Contributor
What potential risks could be associated with administering LN-145 to patients?
"With prior data backing its safety, but limited evidence for efficacy, LN-145 was assigned a score of 2 out of 3." - Anonymous Online Contributor
Is this research effort currently enrolling volunteers?
"Affirmative. The clinicaltrials.gov website attests that this medical experiment, first posted on June 22nd 2017, is presently looking for participants. Approximately 189 people need to be recruited from 19 different sites." - Anonymous Online Contributor
Are there various sites in the city that are conducting this experiment?
"Eligible patients may be recruited to this clinical trial in three major sites, including University of Southern California Los Angeles (California), University of Chicago (Illinois) and University of California San Diego (Florida). Additionally, there are 19 other recruitment centres." - Anonymous Online Contributor
What is the aim of this investigation?
"This clinical trial's primary goal is to gauge the efficacy and adverse events of LN-145 over a 60 month period. Secondary objectives include measuring disease control rate, overall survival, and side effects in patients with recurrent, metastatic or persistent cervical carcinoma as per RECIST v1.1 guidelines." - Anonymous Online Contributor
What is the sample size of this research experiment?
"Iovance Biotherapeutics, Inc. has set a target of 189 participants for this trial; these individuals must meet the defined inclusion criteria in order to be eligible. This clinical study will take place at University of Southern California and University of Chicago, amongst other medical facilities." - Anonymous Online Contributor
Have any preceding investigations explored the use of LN-145?
"LN-145 was initially analyzed in 2010 at the City of Hope. Presently, there are 250 studies that have been completed as well as 961 active trials taking place largely within Los Angeles County." - Anonymous Online Contributor